The COVID Project
The record
- Jurisdiction
- United States (federal); Drug Enforcement Administration, Diversion Control Division
- Level
- Federal
- Authority
- 21 U.S.C. 822(e); 21 C.F.R. 1301.12; 21 C.F.R. 1307.03
- Issued
- 2020-04-07 Apr. 7, 2020
- Effective
- 2020-04-07
- End
- During the public health emergency or until withdrawn or modified by DEA (read as 2021-09-30)
- In force
- Apr. 7, 2020 to Sept. 30, 2021
- Quarters
- 2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3
- Limitation types
- Health care ordersOther
- Addressees
- DEA-registered narcotic treatment programs
- Functions reached
- CL clinical dispensing
- TR transport
- CB patients
- Collection
- Other federal health agencies AGY-FED-HEALTH-OTHER
Operative words
DEA, following consultation with SAMHSA, is issuing this letter to provide OTPs with greater flexibility in how they deliver take-home doses of methadone to their patients. DEA is doing so by temporarily allowing OTPs to repeatedly use the same off-site location to deliver take-home methadone doses to their patients without separately registering that location with DEA, subject to certain conditions.
Enforcement
Registration requirements under 21 U.S.C. 822(e) and 842
Notes
Opioid treatment programs restructured dosing around distancing and quarantine.